Diagnosis and treatment of metastatic and castration resistant prostate cancer became more and more and complex due to the increasing knowledge and understanding of the underlying molecular events and the subsequently deducted innovative medical treatment.
Modern imaging studies in CRPC have become more selective and currently include positron emission tomography, whole body magnetic resonance imaging, immunoscintigraphy besides the traditional studies such as bone scans and computed tomography.
Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer
Raya Leibowitz-Amit, Arnoud J. Templeton, Shabbir M. Alibhai, Jennifer J. Knox, Srikala S. Sridhar, Ian F. Tannock, Anthony M. Joshua
Journal of Geriatric Oncology, 1, 6, pages 23 - 28
Salvatore L. Burgio, Vincenza Conteduca, Britt Rudnas, Francesco Carrozza, Enrico Campadelli, Emanuela Bianchi, Paolo Fabbri, Marco Montanari, Elisa Carretta, Cecilia Menna, Ugo De Giorgi
Clinical Genitourinary Cancer
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer
Prof Charles J Ryan, MD, Prof Matthew R Smith, MD, Prof Karim Fizazi, MD, et al.The Lancet Oncology, Volume 16, No. 2, p152–160, February 2015
Sciarra A, Gentile V, Cattarino S, Gentilucci A, Alfarone A, D'Eramo G, Salciccia S.Int J Urol. 2015 Jan;22(1):98-103. doi: 10.1111/iju.12613. Epub 2014 Sep 3.
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study
Michael T. Schweizer,†, Emmanuel S. Antonarakis, Hao Wang, A. Seun Ajiboye, Avery Spitz, Haiyi Cao, Jun Luo, Michael C. Haffner, Srinivasan Yegnasubramanian, Michael A. Carducci, Mario A. Eisenberger, John T. Isaacs and Samuel R. Denmeade†Sci Transl Med 7 January 2015: Vol. 7, Issue 269, p. 269ra2 Sci. Transl. Med. DOI: 10.1126/scitranslmed.3010563
About the editors
- Professor Miller has been Chairman and Professor of Urology for the Department of Urology at the Benjamin Franklin Medical Center, Berlin, Germany, since 1993. In 2007 he became Chairman of the Department of Urology for the entire Charité (Campus Benjamin Franklin, Campus Mitte and Campus Virchow Klinikum). With more than 6000 in-patients per year, the Dep. of Urology at the Charité is one the largest urologicals clinics in Europe.
- Prof Axel S. Merseburger is currently Vice Chairman of the Department of Urologic Oncology, as well as Director of the Urologic Oncology Programme at Hannover Medical School, Germany. Professor Merseburger obtained his medical degree from Hannover Medical School in 2002 following a 1-year academic research programme in Washington D.C., USA, where he finished his M.D. thesis.
- Apr 201511Apr 201514Welcome to the 2015 USANZ Annual Scientific Meeting (ASM), the 68th Meeting of the Urological communities of Australia and New...
- Apr 201517Apr 201518Contact: Central Offi ce Urological Association of Serbia Tel.: +381 11 2656277 E-mail: email@example.com